臨床泌尿器科63巻5号

2009年04月発行

特集 泌尿器科の癌薬物療法―ここが聞きたい

膀胱癌―今日においてもBCGおよびMVACは標準治療か？

著者： 塚本泰司¹ 田中俊明¹

所属機関： ¹札幌医科大学医学部泌尿器科

ページ範囲：P.311 - P.316

文献概要

要旨　MVAC療法の効果を凌駕する化学療法がないことからすれば，この治療の効果はサロゲートマーカーとなる。一方，有害事象の面からはGC療法が標準治療となる。しかし，MVAC療法で得られたこれまでの種々の知見が，GC療法に直接当てはまるかどうかは今後の検討が必要である。周術期の化学療法としては現時点では術後よりは術前化学療法が推奨されるが，GC療法を用いた検討は乏しく，これに関した知見の充実が望まれる。High-grade癌に対するBCG膀胱内注入療法は，今後も標準治療である。さらに，その効果を損なうことなく有害事象を軽減できるBCGの投与量，あるいは結核菌のcell wall skeletonなどを使用する他の新しい治療法の開発への挑戦も必要である。

参考文献

1）Hall MC, Chang SS, Dalbagni G, et al：Guideline for the management of nonmuscle invasive bladder cancer（Stages Ta, T1 and Tis）：2007 update. J Urol 178：2314-2330, 2007

2）Babjuk M, Oosterlinck W, Sylvester R, et al：EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54：303-314, 2008

3）Sternberg CN, Donat SM, Bellmunt J, et al：Chemotherapy for bladder cancer：treatment guidelines for neoadjuvant chemotherapy, bladder reservation, adjuvant chemotherapy, and metastatic cancer. Urology 69（suppl. 1A）：62-79, 2007

4）von der Maase H, Senegelov L, Roberts JT, et al：Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23：4602-4608, 2005

5）Sternberg CN, Yogoda A, Scher H, et al：M-VAC（methotrexate, vinblastine, doxorubicin and cisplatin）for advanced transitional cell carcinoma of the urothelium. J Urol 139：461-469, 1988

6）Loehrer PJ, Einhorn LH, Elson PJ, et al：A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma：a cooperative group study. J Clin Oncol 10：1066-1073, 1992

7）Logothetis CJ, Dexeus F, Finn L, et al：A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 8：1050-1055, 1990

8）Sternberg CN, de Mulder PHM, Schornagel JH, et al：Randomized phase Ⅲ trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin（MVAC）chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumot：European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 19：2638-2646, 2001

9）Saxman SB, Propert KJ, Einhorn LH, et al：Long-term follow-up of a phase Ⅲ intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma：a cooperative group study. J Clin Oncol 15：2564-2569, 1997

10）Igawa M, Urakami S, Ishibe T, et al：Long-term results with M-VAC for advanced urothelial cancer：high response relapse rate and low survival in patients with a complete response. Brit J Urol 76：321-324, 1995

11）Hussain SA and James ND：The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 4：489-497, 2003

12）von der Maase H, Hansen SW, Roberts JT, et al：Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer：results of a large, randomized, multinational, multicenter, phase Ⅲ study. J Clin Oncol 17：3068-3077, 2000

13）Akaza H, Naito S, Usami M, et al：Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy：a Japanese experience. Jpn J Clin Oncol 37：201-206, 2007

14）Stenzel A, Cowan NC, de Santis M, et al：The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol, 2009（in press）

15）Bamias A, Aravantinos G, Deliveliotis C, et al：Docetaxel and cisplatin with granulocyte colony-stimulating factor（G-CSF）versus MVAC with G-CSF in advanced urothelial carcinoma：a multicenter, randomized phase Ⅲ study from Hellenic Cooperative Oncology Group. J Clin Oncol 22：220-228, 2004

16）Bellmunt J, von der Maase H, Mead GM, et al：Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine（PCG）and gemcitabine/cisplatin（GC）in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy：EORTC30987/Intergroup study. J Clin Oncol 25（18S）：LBA5030, 2007

17）Sonpavde G and Sternberg CN：Treatment of metastatic urothelial cancer：opportunities for drug discovery and development. BJU Int 102：1354-1360, 2008

18）Shinihara N, Harabayashi T, Suzuki S, et al：Salvage chemotherapy with paclitaxel, ifosphamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. Cancer Chemother Pharmacol 58：402-407, 2006

19）塚本泰司，前田俊浩，福多史昌：筋層浸潤膀胱癌におけるneoadjuvant chemotherapyの意義．泌尿器外科 20：1137-1145，2007

20）Advanced Bladder Cancer（ABC）Meta-analysis Collaboration：Neoadjuvant chemotherapy in invasive bladder cancer：update of a systematic review and meta-analysis of individual patient data. Eur Urol 48：202-206, 2005

21）Grossman HB, Natale RB, Tangen CM, et al：Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med 349：859-866, 2003

22）Dash A, Pettus JA, Herr HW, et al：A role of neoadjuvant gemicitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder：a retrospective experience. Cancer 113：2471-2477, 2008

23）Nelson ME：Neoadjuvant gemcitabine and cisplatin：another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer. Cancer 113：2379-2381, 2008

24）Hinotsu S, Akaza H, Ohashi Y, et al：Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection：a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86：1818-1826, 1999

25）Sylvester RJ, Oosterlinck W and von der Meijden APM：A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta, T1 bladder cancer：meta-analysis of published results of randomized clinical trials. J Urol 171：2186-2190, 2004

26）福多史昌，前田俊浩，塚本泰司：膀胱癌の化学療法，外科治療 98（増刊）：717-723，2008

27）Koga H, Kuroiwa K, Yamaguchi A, et al：A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 171：153-157, 2004

28）Bohle A and Bock PR：Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer：formal meta-analysis of comparative studies on tumor progression. Urology 63：682-687, 2004

29）Witjes JA and Hendricksen K：Intravesical pharmacotherapy for non-muscle-invasive bladder cancer：a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53：45-52, 2008

30）Morales A：Evolution of Intravesical imunothearapy for bladder cancer：mycobacterial cell wall preparation as promising agent. Expert Opin Investig Drugs 17：1067-1073, 2008

bacillus Calmette-Guerin. BJU Int, 2008 Nov 25.［Epub ahead of print］